U.S. Hemophilia Treatment Market 규모 및 점유율 분석 - 성장 추세 및 예측 (2024 - 2031)
U.S. Hemophilia Treatment Market is Segmented By Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Others), By Disease Type (Hemophilia A, Hemophilia B, and Hemophilia C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). The report offers the value (in USD billion) for the above-mentioned segments.
Competitive overview of U.S. Hemophilia Treatment Market
미국 hemophilia 치료 시장에서 운영되는 주요 선수는 Takeda Pharmaceutical Company Limited를 포함합니다. Sanofi Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc. 및 Spark Therapeutics, Inc.
U.S. Hemophilia Treatment Market Leaders
- 다케다제약 회사 제한
- 산피 Octapharma AG
- 스웨덴 Orphan Biovitrum AB
- Baxter 국제 주요사업
- (주)바이오젠
*Disclaimer: Major players are listed in no particular order.
U.S. Hemophilia Treatment Market - Competitive Rivalry, 2023
U.S. Hemophilia Treatment Market
Market Consolidated
(Dominated by major players)
(Dominated by major players)
Market Fragmented
(Highly competitive with lots of players.)
(Highly competitive with lots of players.)
*Source: Coherent Market Insights